HBsAg Specific Neutra™ Antibody Products
Product listHepatitis B surface antigen (HBsAg), also referred to as the Australia antigen, is a crucial surface antigen for the hepatitis B virus (HBV). HBsAg is recognized for protecting its high-affinity binding to HBsAg, which is the primary constituent of the virus envelope, along with the 22-nanometer subviral particles. Its detection in the bloodstream signals an ongoing hepatitis B infection.
Immunotherapy with HBsAg-Specific Antibodies
Achieving HBsAg seroclearance represents the goal of HBV treatment. Current medications for treating HBV, such as interferons and nucleos(t)ide analogs, can only induce remission of the disease and are not highly effective in achieving a functional cure for patients with chronic HBV infection (CHB). High levels of circulating HBsAg may play a key role in evading the host's anti-HBV immune response, as shown in Fig.1. Infected hepatocytes generate and release substantial quantities of HBV envelope polypeptides, which are also present in HB virions. These polypeptides play a role in suppressing adaptive immune responses.
Using HBsAg-specific antibodies for immunotherapy offers an alternative strategy, directly suppressing HBsAg. Monoclonal antibodies targeting HBV envelope proteins (HBs-mAbs) have the potential to decrease peripheral protein load, which may facilitate the restoration of B and T-cell-mediated immune responses. Therefore, this innovative approach holds promise for reviving virus-specific immune responses and aiding in virus elimination.
Fig.1 Effect of HBV infection on immune responses.1
Therapeutic Effects and Mechanisms of HBsAg-Specific Antibodies
Antibodies are believed to exert antiviral effects by either blocking viral entry into cells or accelerating viral clearance from the bloodstream. When administeredin vivo, virus-specific antibodies can serve multiple therapeutic roles. Neutralizing antibodies, which bind to and deactivate viral envelope proteins, effectively prevent virus entry, thereby halting infection spread. Additionally, specific antibodies may possess intrinsic effector functions that aid in directly eliminating circulating viruses, viral antigens, or virus-producing cells through mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC), complement-mediated cytotoxicity (CDC), or antibody-dependent cellular phagocytosis (ADCP). Furthermore, the formation of complexes between antibodies and viruses binds to Fc receptors expressed by immune effector cells, triggering a range of innate and adaptive responses against viruses. Therefore, antibodies targeting HBsAg offer protection by binding to circulating virus particles.
Creative Biolabs provides a variety of anti-HBsAg antibody products for use in various applications. If you need more information or a quote, please contact us. We guarantee a response within 24 hours and will work with you to design the optimal method for your project.
REFERENCE
- Cerino, Antonella, et al. "Human monoclonal antibodies as adjuvant treatment of chronic hepatitis B virus infection." Frontiers in immunology 10 (2019): 2290. Under open access license CC BY 4.0, without modification.
